Asset profile

pelacarsen · Royalty Pharma (RPRX)

Indication: elevated Lp(a) and established cardiovascular disease

Company

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, includin…

Start live analysis of RPRX Run 8-agent AI analysis Stock overview

On the calendar

Feb 2028

Feb 3, 2028

in 505 days

RPRXRoyalty Pharma

pelacarsen: Phase 3 trial NCT06813911 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.gov

Aug 2028

Aug 24, 2028

in 708 days

RPRXRoyalty Pharma

pelacarsen: Phase 3 trial NCT05900141 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.gov

Dec 2028

Dec 7, 2028

in 813 days

RPRXRoyalty Pharma

pelacarsen: Phase 3 trial NCT07625306 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.gov

Jan 2030

Jan 9, 2030

in 1211 days

RPRXRoyalty Pharma

pelacarsen: Phase 3 trial NCT07517263 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.gov

Mar 2030

Mar 12, 2030

in 1273 days

RPRXRoyalty Pharma

pelacarsen: Phase 2 trial NCT05646381 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.gov

Dec 2030

Dec 8, 2030

in 1544 days

RPRXRoyalty Pharma

pelacarsen: Phase 3 trial NCT06875973 expected to finish collecting primary-endpoint data (topline results usually follow)

Trial primary completionClinicalTrials.gov

Timeline

Newest first.

Decision-grade

Sep 4, 2026

11:05 PM

RPRXRoyalty Pharma

Royalty Pharma: Novartis pelacarsen HORIZON Phase 3 misses primary endpoint

Topline resultsCompany press release Open record1 update

Readiness checklist

Public facts only. We never publish an approval probability.

Updated Sep 15, 2026

Primary endpoint metConcern

Royalty Pharma: Novartis pelacarsen HORIZON Phase 3 misses primary endpoint

Overall survival significant or trendingUnknown

US / Western patient shareFavourable

665 of 2007 sites in the United States

Advisory committee scheduledFavourable

No advisory committee announced

PDUFA date extendedUnknown

Manufacturing inspection recordUnknown

No public inspection record

Company language signals (label discussions)Unknown

Same-class precedentUnknown

Related companies

Each relationship is backed by the filing that stated it.

IONSIonisOwner

Company press release Sep 4, 2026

IONSIonisPartner

Company press release Sep 4, 2026

NVSNovartisPartner

Company press release Sep 4, 2026
Company press release Sep 4, 2026

RPRXRoyalty PharmaOwner

Company press release Sep 4, 2026

Verify every date against the linked primary source. Informational only. Not investment advice. SimianX is not affiliated with the FDA or the SEC.

Registered trials

Registry ID	Phase	Status	Primary completion	Enrollment	Sites
NCT07517263	Phase 3	Recruiting	Jan 9, 2030	5700	124 of 655 sites in the United States
NCT06813911	Phase 3	Recruiting	Feb 3, 2028	340	36 of 95 sites in the United States
NCT05900141	Phase 3	Active, not recruiting	Aug 24, 2028	41	0 of 9 sites in the United States
NCT04023552	Phase 3	Completed	Jul 16, 2026	8323	287 of 902 sites in the United States
NCT05646381	Phase 2	Recruiting	Mar 12, 2030	502	38 of 140 sites in the United States
NCT06267560	Phase 3	Completed	Mar 25, 2026	422	89 of 96 sites in the United States
NCT05305664	Phase 3	Completed	Jan 28, 2025	51	0 of 13 sites in the United States
NCT07625306	Phase 3	Not yet recruiting	Dec 7, 2028	240
NCT06875973	Phase 3	Recruiting	Dec 8, 2030	599	91 of 97 sites in the United States

More from Royalty Pharma

Other drugs and candidates from the same company tracked in this sector.

aficamtensymptomatic non-obstructive hypertrophic cardiomyopathy (nHCM)daraxonrasibmetastatic pancreatic cancer obexelimabImmunoglobulin G4-Related Disease (IgG4-RD)tividenofusp alfaHunter syndrome (mucopolysaccharidosis type II; MPS II)